RxDoctor Payments Data

Henry Paez, MD

Family Medicine · Miami, FLNPI 1093790313

Payments from drug & device makers

$2,051,404in general payments, 2019–2025

Across 890 payments — averaging $2304.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$877K
  • Esperion Therapeutics, Inc.$414K
  • Pfizer$350K
  • AstraZeneca$319K
  • Novartis$70K
  • Astrazeneca UK Limited$13K
  • plus $9K from 17 others

What the payments were for

  • Food & beverage$1,579100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,051,404 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$61,826
Medicare patients
108
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$96,587
EliquisApixaban110$69,537
TradjentaLinagliptin71$41,315
LinzessLinaclotide41$38,816
MounjaroTirzepatide21$26,318
FarxigaDapagliflozin Propanediol27$22,424
EntrestoSacubitril/Valsartan25$20,491
VascepaIcosapent Ethyl41$19,755
JanuviaSitagliptin Phosphate11$16,852
XareltoRivaroxaban17$12,836
SynjardyEmpagliflozin/Metformin Hcl11$8,058
SymbicortBudesonide/Formoterol Fumarate20$5,479
FiaspInsulin Aspart (Niacinamide)14$4,369
Memantine Hcl91$3,721
Humalog Kwikpen U-100Insulin Lispro14$3,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp$34$100,956112 claims
PfizerEliquis$349,881$69,537110 claims
Boehringer IngelheimTradjenta, Synjardy$264$49,37382 claims
AbbVieLinzess, Combigan$88$41,21853 claims
AstraZenecaFarxiga, Symbicort$318,685$27,90247 claims
NovartisEntresto$69,959$20,49125 claims
MerckJanuvia$500$16,85211 claims
Johnson & JohnsonXarelto$99$12,83617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →